Dr. Sreenivasa S. Jonnalagadda, MD

Dr. Jonnalagadda practices at Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health.

Dr. Jonnalagadda's NPI, 1376569673, was assigned on July 14, 2006. Dr. Jonnalagadda holds Missouri license 101430.

Dr. Jonnalagadda's primary practice is Saint Luke's Hospital of Kansas City, at 4401 Wornall Road, Kansas City, MO 64111 in Jackson County. The practice phone is (816) 932-2000.

Dr. Jonnalagadda's primary practice is Saint Luke's Hospital of Kansas City in Kansas City, Missouri, part of BJC Health. Dr. Jonnalagadda is also affiliated with Saint Luke's North Hospital-Barry Road. The medical group on file is Saint Luke's Medical Group. Dmand AI also links Dr. Jonnalagadda to 3 more hospitals, 1 group practice or clinic and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jonnalagadda practices, 7 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Jonnalagadda's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Jonnalagadda's licenses on file in 2 states: Missouri and Kansas.

CMS data shows 764 Medicare services from Dr. Jonnalagadda across 22 procedure codes in 2024, for 495 Medicare patients. Medicare paid $109,353 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 495 Medicare patients who saw Dr. Jonnalagadda in 2024. The largest group is 65 to 74, with 202 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jonnalagadda's median patient age at 72, with 55% women.

In 2024, Dr. Jonnalagadda wrote 480 Medicare Part D claims for 271 patients. 75% of them were for generic drugs. CMS names the drug for 387 of them, across 11 drugs with 11 or more claims each, at $58,840 in total drug cost. In 2023, CMS named 486 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Jonnalagadda for performance year 2024, reported as part of a group. Dr. Jonnalagadda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jonnalagadda as offering telehealth. CMS counts 779 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Jonnalagadda, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 20 papers to Dr. Jonnalagadda, published from 2011 to 2024. 2011 was the busiest year, with 3. The most frequent topics are Cholangiopancreatography, Endoscopic Retrograde, Endoscopy and Endoscopy, Gastrointestinal. Dr. Jonnalagadda has published most often in Gastrointest Endosc. Dr. Jonnalagadda's most frequent co-authors are Dayna S. Early, MD, Steven A. Edmundowicz, MD and Daniel Kast Mullady, MD.

CMS Open Payments shows 29 general payments to Dr. Jonnalagadda from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Exact Sciences Corporation paid the most, $3,374.